Range Impact Inc (RNGE)

[superchg2]

I hadn't looked at the team recently, and there she is. She has a great deal of valuable background related to treating inflammatory bowel disease, which is one of VBIO's main focuses.

"In January 2007, during her tenure with Shire, Ms. Rockney led the regulatory team and negotiations with FDA for LIALDA™. The FDA approved Shire’s LIALDA™ with MMX® technology, which was the first once-daily oral formulation of mesalamines. Mesalamines are part of the drug class of aminosalicylates, now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had U.S. sales in 2016 of $714 million, which increased by 16% relative to 2015 sales."

http://vitality.bio/2017/04/vitality-biopharma-appoints-pharma-industry-veteran-advance-cannabosides-regulatory-development/